Clinical trial
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally…
NCT00266110 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00266110 |
|---|---|
| Title | Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
| Official title | Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Susan G. Komen Breast Cancer Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate |
| Enrollment | 17 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2013 |
| Completion | Oct 27, 2017 |
| First posted | Dec 15, 2005 |
| Last update posted | Sep 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: